Susceptibility of Staphylococcus aureus from Hospitalised Patients to Topical Antimicrobials in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(2):157-163

​ Stratchounski L.S., Dekhnich A.V., Belkova Yu.А., The StEnt Study Group
Staphylococcus aureus topical antimicrobials antimicrobial resistance fusidic acid mupirocin
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(2):157-163

Objective.

To determine in vitro activity of fusidic acid and other antimicrobials available for topical use against S. aureus isolated from hospitalised patients.

Materials and Methods.

A total of 879 clinical strains of S. aureus isolated in 2000-2001 from patients hospitalised in 17 medical institutions in different parts of Russia - 4 in Central region, 2 in North-West region, 3 in South region, 2 in Volga region, 3 in Ural region, 3 in Siberian region, were included in the study. Susceptibility to fusidic acid and 8 other antimicrobials available for topical use (gentamicin, mupirocin, erythromycin, clindamycin, lincomycin, tetracycline, chloramphenicol, ciprofloxacin) was determined by agar dilution method in accordance with the NCCLS recommendations.

Results.

The most potent antimicrobial was fusidic acid to which no resistance was found. The only other antimicrobial with low frequency of resistance was mupirocin (0,3% of the lower-level resistance). The prevalence of MRSA among tested strains was 33,6%. The high rates of resistance were found to erythromycin (39,6%), tetracycline (37,1%), gentamicin (30,7%), clindamycin (27,1%), ciprofloxacin (13,1%) and chloramphenicol (43,1%).

Conclusions.

Fusidic acid and mupirocin can by used as the drugs of choice for the treatment of S. aureus infections in Russia. High rate of resistance to chloramphenicol, macrolides, tetracyclines, aminoglycosides and lincosamydes advise not to use these antimicrobials for empiric therapy of S. aureus infections.

  • 1. Каламкарян А.А., Архангельская Е.И., Глухенький Б.Т., Масюкова С.А. Кожные и венерические болезни. Под редакцией Скрипкина Ю.К., Мордовцева В.Н. 2-е изд. Москва: Медицина; 1999. Т. 1. с. 213-57.
  • 2. Trilla A., Miro J.M. Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. J Chemother 1995; 7 (Suppl 3):37-43.
  • 3. Mandell L.A. In: Mandell G.L., Bennett J.E., Raphael D., editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston; 2000. p. 306-7.
  • 4. Jorgensen J.H. Laboratory and epidemiologic experience with methicillin-resistant Staphylococcus aureus in the USA. Eur J Clin Microbiol 1986; 5:693-6.
  • 5. Kallen A., Driscoll T., Thornton S., Olson P., Wallace M. Increase in community-acquired methicillin-resistant Staphylococcus aureus at a naval medical center. Infect Control Hosp Epidemiol 2000; 21:223-6.
  • 6. O’Brien F., Pearman J., Gracey M., Riley T., Grubb W. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999; 37:2858-62.
  • 7. Gosbell I.B., Mercer J.L., Neville S.A., Chant K.G., Munro R. Community-acquired, non-multiresistant oxacillinresistant Staphylococcus aureus (NORSA) in south western Sydney. Pathology 2001; 33(2):206-10.
  • 8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. NCCLS Document M100-S4. 2002; 22(1).
  • 9. Statement 1996 CA-SFM. Zone sizes and MIC breakpoints for non-fastidious organisms. Clin Microbiol Infect 1996; 2 (Suppl 1):46-9.
  • 10. Богданович Т.М., Страчунский Л.С. Мупироцин: уникальный антибиотик для местного применения. Клин микробиол антимикроб химиотер 1999; 1(1):57-65.
  • 11. Белькова Ю.А. Фузидовая кислота в современной клинической практике (Обзор литературы). Клин микробиол антимикроб химиотер 2001; 4:324-38.
  • 12. Reynolds J.I.F., editor. Martindall the extra pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society; 1996. p. 233-5.
  • 13. Turnidge J., Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl 2):35-44.
  • 14. Samra Z., Gadba R., Ofir O. Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at the period during 1991–1997. Eur J Clin Microbiol Infect Dis 2001; 20:427-7.
  • 15. O’Neill A.J., Cove J.H., Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47:647-50.
  • 16. Kochman M., Fordymacki P., Lawrynowicz-Pacior M., et al. Susceptibility to selected chemotherapeutics Staphylococcus aureus strains resistant to methicilline isolated from clinical materials in the years 1991–1992 and 1997. Med Dosw Microbiol 1999; 51(3-4):187-98.
  • 17. Perez-Fontan M., Rosales M., Rodriguez-Carmona A., Falcon T.G., Valdes F. Mupirocin resistance after longterm use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39(2):337-41.
  • 18. Nishijima S., Kurokawa I. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections. Int J Antimicrob Agents 2002; 19:241-3.
  • 19. Guerin F., Buu-Hoi A., Mainardi J.-L., et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Parisian hospital. J Clin Microbiol 2000; 38:2985-8.
  • 20. Rohani M.Y., Raudzah A., Lau M.G., et al. Susceptibility pattern of Staphylococcus aureus isolated in Malaysian hospitals. Int J Antimicrob Agents 2000; 13:209-13.
  • 21. Swarz M.N. Use of antimicrobial agents and drug resistance. N Engl J Med 1997; 337:491-2.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared